Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments

被引:21
作者
Petagine, Lucy [1 ]
Zariwala, Mohammed Gulrez [1 ]
Patel, Vinood B. [1 ]
机构
[1] Univ Westminster, Sch Life Sci, Ctr Nutraceut, 115 New Cavendish St, London W1W 6UW, England
关键词
Liver; Fat; Inflammation; Mitochondria; Immune system; CELL-ACTIVATING FACTOR; HEPATIC STEATOSIS; EXTRACELLULAR VESICLES; INSULIN-RESISTANCE; KUPFFER CELLS; CIRCULATING MICRORNAS; METABOLIC SYNDROME; UNITED-STATES; B-CELLS; STEATOHEPATITIS;
D O I
10.3748/wjg.v29.i32.4831
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Non-alcoholic fatty liver disease (NAFLD) causes significant global disease burden and is a leading cause of mortality. NAFLD induces a myriad of aberrant changes in hepatocytes at both the cellular and molecular level. Although the disease spectrum of NAFLD is widely recognised, the precise triggers for disease progression are still to be fully elucidated. Furthermore, the propagation to cirrhosis is poorly understood. Whilst some progress in terms of treatment options have been explored, an incomplete understanding of the hepatic cellular and molecular alterations limits their clinical utility. We have therefore reviewed some of the key pathways responsible for the pathogenesis of NAFLD such as innate and adaptative immunity, lipotoxicity and fibrogenesis, and highlighted current trials and treatment options for NAFLD patients.
引用
收藏
页码:4831 / 4850
页数:20
相关论文
共 178 条
[1]   Fecal Microbiota Transplantation in NAFLD Treatment [J].
Abenavoli, Ludovico ;
Maurizi, Valentina ;
Rinninella, Emanuele ;
Tack, Jan ;
Di Berardino, Arianna ;
Santori, Pierangelo ;
Rasetti, Carlo ;
Procopio, Anna Caterina ;
Boccuto, Luigi ;
Scarpellini, Emidio .
MEDICINA-LITHUANIA, 2022, 58 (11)
[2]   β-Hydroxybutyrate in the Brain: One Molecule, Multiple Mechanisms [J].
Achanta, Lavanya B. ;
Rae, Caroline D. .
NEUROCHEMICAL RESEARCH, 2017, 42 (01) :35-49
[3]   Intrahepatic natural killer T cell populations are increased in human hepatic steatosis [J].
Adler, Michael ;
Taylor, Sarah ;
Okebugwu, Kamalu ;
Yee, Herman ;
Fielding, Christine ;
Fielding, George ;
Poles, Michael .
WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 17 (13) :1725-1731
[4]   Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease [J].
Alexander, Myriam ;
Loomis, A. Katrina ;
Fairburn-Beech, Jolyon ;
van der Lei, Johan ;
Duarte-Salles, Talita ;
Prieto-Alhambra, Daniel ;
Ansell, David ;
Pasqua, Alessandro ;
Lapi, Francesco ;
Rijnbeek, Peter ;
Mosseveld, Mees ;
Avillach, Paul ;
Egger, Peter ;
Kendrick, Stuart ;
Waterworth, Dawn M. ;
Sattar, Naveed ;
Alazawi, William .
BMC MEDICINE, 2018, 16
[5]   Frequency of non-alcoholic fatty liver disease (NAFLD) and its associated risk factors among Type-2 diabetics [J].
Ali, Alia ;
Amin, Muhammad Joher ;
Ahmed, Muhammad Uthman ;
Taj, Azeem ;
Aasim, Muhammad ;
Tabrez, Elsa .
PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2022, 38 (01) :28-33
[6]   Plasma Myeloperoxidase Levels Correlate with the Presence of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease [J].
Alkhouri, Naim ;
Li, Lin ;
Hanouneh, Ibrahim ;
Feldstein, Ariel ;
Hazen, Stanley .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 :S181-S181
[7]   Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study [J].
Allen, Alina M. ;
Therneau, Terry M. ;
Larson, Joseph J. ;
Coward, Alexandra ;
Somers, Virend K. ;
Kamath, Patrick S. .
HEPATOLOGY, 2018, 67 (05) :1726-1736
[8]  
Ando Yumi, 2021, Clin Liver Dis (Hoboken), V17, P23, DOI [10.1002/cld.1045, 10.1002/cld.1045]
[9]  
[Anonymous], 2021, Cancer Discov, V11, pOF31, DOI [10.1158/2159-8290.cd-rw2021-047, 10.1158/2159-8290.CD-RW2021-047]
[10]   Innate Immunity and Inflammation in NAFLD/NASH [J].
Arrese, Marco ;
Cabrera, Daniel ;
Kalergis, Alexis M. ;
Feldstein, Ariel E. .
DIGESTIVE DISEASES AND SCIENCES, 2016, 61 (05) :1294-1303